0000704562 false 0000704562 2021-11-04 2021-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, DC 20549










Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 4, 2021





(Exact name of registrant as specified in its charter)


Delaware 001-32839 95-3698422
(State of other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)


2642 Michelle Drive, Suite 200, Tustin, California 92780

(Address of Principal Executive Offices)


Registrant’s telephone number, including area code: (714) 508-6100



(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each Class Trading Symbol Name of each exchange on which registered
Common Stock, $0.001 par value per share CDMO The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

   Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








On November 4, 2021, Avid Bioservices, Inc. (the “Company”) issued a press release announcing the appointment of Elie G. Hanania, Ph.D, as the Company’s Vice President, Process Development, Viral Vector Technologies. A copy of the press release is filed hereto as Exhibit 99.1.




(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:





99.1 Press Release issued November 4, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).










Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 4, 2021 By: /s/ Daniel R. Hart
    Daniel R. Hart
    Chief Financial Officer











Number Description
99.1 Press Release issued November 4, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).



















Exhibit 99.1


Logo no tagline


Stephanie Diaz (Investors)   Tim Brons (Media)
Vida Strategic Partners   Vida Strategic Partners
415-675-7401   415-675-7402
sdiaz@vidasp.com   tbrons@vidasp.com



Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies


Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth Biotechnologies and Millipore Sigma


TUSTIN, CA, November 4, 2021 -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Elie G. Hanania, Ph.D., as vice president, process development, viral vector technologies. Dr. Hanania is a seasoned life science industry executive with more than 30 years of experience in the field of cell and gene therapy. Avid recently announced the expansion of its CDMO service offering into the rapidly growing cell and gene therapy market and Dr. Hanania’s appointment represents a key addition to the dedicated team that will be responsible for leading the company’s efforts in this area.


Dr. Hanania has broad expertise across the cell and gene therapy field that spans discovery, research, development, viral vector manufacturing, and gene therapy clinical application. This includes an established track record of success in developing and implementing state-of-the-art enabling technologies for viral vector production and purification processes focused on adeno-associated viruses (AAVs), lentiviruses, oncolytic viruses and other viruses for gene therapy and vaccine applications. Prior to joining Avid, Dr. Hanania most recently served as director, upstream process development for Fujifilm Diosynth Biotechnologies, where he led the process development team in charge of upstream production of all viral vectors and therapeutic proteins. He has also spent more than a decade in senior level process development positions with Millipore Sigma, the life science business of Merck KGaA, Darmstadt, Germany, including several years as the company’s head of process development. In this role, Dr. Hanania managed the process development team responsible for viral vector upstream production, downstream purification, tech-transfer to CGMP manufacturing, and late-stage process characterization and validation. These efforts were critical in supporting both clinical and commercial manufacturing activities. Dr. Hanania began his career as a research scientist in the hematology department at the University of Texas, M.D. Anderson Cancer Center. He earned a Ph.D. in cell and molecular biology from the University of Texas Medical Branch.


“As part of our strategic expansion into the cell and gene therapy, we are committed to building an industry-leading team of viral vector experts with established track records of success in this cutting-edge field. Dr. Hanania is the perfect representation of the type of exemplary individual that we are seeking to build our viral vector team around,” said Drew Brennan, general manager of viral vector technologies of Avid Bioservices. “Dr. Hanania possesses all of the essential expertise required for leading an innovative viral vector process development service offering. Importantly, he has been involved in this growing sector, working intimately with the evolving science that has enabled its maturation, for multiple decades. This unique level of experience will prove critical in helping establish Avid as one of the CDMO industry’s most trusted partners in the area of viral vectors.”


Avid’s expansion into viral vector development and manufacturing is driven by continued strong growth in the cell and gene therapy market combined with the CDMO industry’s overall lack of proven, high-quality CGMP manufacturing expertise and capacity for viral vectors. With more than 16 years of experience in commercial manufacturing of biologics underpinned by a strong quality ethos and a customer-centric approach to doing business, Avid offers a strong value proposition to prospective customers in the cell and gene therapy market.


The company is constructing a world-class, purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA, approximately five miles from Avid’s existing operations in Tustin, CA. Based on current projections, Avid expects the entire new facility build out to take up to 18 months at an estimated cost of approximately $75 million. The new facility’s analytical and process development laboratories are expected to come online more rapidly, with the potential to be operational during the first quarter of fiscal 2023.





About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com


Forward-Looking Statements


Statements in this press release which are not purely historical, including statements regarding Avid Bioservices, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company may experience delays in the construction of viral vector facility, the risk that expanding into a new biologics manufacturing segment may distract senior management’s focus on the company’s existing operations and/or its current expansion of the Myford facility, the risk that the company may experience delays in hiring qualified individuals into the viral vector business, the risk that the company may experience delays in engaging initial customers for the viral vector business, and the risk that the viral vector business may not become profitable for several years, if ever. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2021 and subsequent quarterly reports on Form 10-Q, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law.